PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32289483-3 2020 Herein, we designed the protein-drug conjugate HSAP-DC-CAT (human serum albumin/Pt (IV)-dibenzocyclooctyne/chlorin e6-catalase) by modification of CAT and cisplatin pro-drug loaded HSA with pH-sensitive azide linker 3-(azidomethyl)-4-methyl-2,5-furandione (AzMMMan) followed by click chemistry assembly with DC. Platinum 80-82 albumin Homo sapiens 66-79 32070915-0 2020 Anionic versus neutral Pt(II) complexes: The relevance of the charge for human serum albumin binding. Platinum 23-29 albumin Homo sapiens 79-92 32070915-1 2020 The focus of this work is pointing out the different behavior of two structurally related Pt(II) complexes, the anionic cyclometalated NBu4[(Bzq)Pt(Thio)], 1 and the neutral [(Phen)Pt(Thio)], 2, (Bzq = benzo[h]quinoline, Phen = 1,10-phenantroline, Thio = 1,2-benzenedithiolate), on the interaction with human serum albumin (HSA), a key drug-delivery protein in the bloodstream. Platinum 90-96 albumin Homo sapiens 309-322 31219025-0 2019 Albumin-Encapsulated Platinum Nanoparticles for Targeted Photothermal Treatment of Glioma. Platinum 21-29 albumin Homo sapiens 0-7 31388926-0 2020 Kinetic and Thermodynamic Investigation of Human Serum Albumin Interaction with Anticancer Glycine Derivative of Platinum Complex by Using Spectroscopic Methods and Molecular Docking. Platinum 113-121 albumin Homo sapiens 55-62 31388926-3 2020 The interaction of human serum albumin (HSA) with Pt complex was studied by using UV-Vis, fluorescence spectroscopy methods, and molecular docking at 27 and 37 C in the physiological situation (I = 10 mM, pH = 7.4). Platinum 50-52 albumin Homo sapiens 25-38 31721562-12 2019 The average binding distance (r) between Pt(II) complexes and HSA is obtained by Forster"s resonance energy-transfer theory. Platinum 41-43 albumin Homo sapiens 62-65 31219025-2 2019 In this study, we utilized the human serum albumin (HSA) as a template to synthesize ultrasmall platinum nanoparticle for targeted photothermal treatment of glioma. Platinum 96-104 albumin Homo sapiens 37-50 17992278-0 2007 Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Platinum 31-39 albumin Homo sapiens 78-91 27844009-1 2015 The interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the distribution, metabolism, and activity of platinum-based anticancer drugs. Platinum 25-33 albumin Homo sapiens 54-67 27844009-1 2015 The interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the distribution, metabolism, and activity of platinum-based anticancer drugs. Platinum 142-150 albumin Homo sapiens 54-67 25038538-0 2014 Choline and acetylcholine detection based on peroxidase-like activity and protein antifouling property of platinum nanoparticles in bovine serum albumin scaffold. Platinum 106-114 albumin Homo sapiens 139-152 25038538-1 2014 Platinum nanoparticles (PtNPs) in the scaffold of bovine serum albumin (BSA) through biomineralization are found to possess excellent peroxidase-like activity that can catalyze N-ethyl-N-(3-sulfopropyl)-3-methylaniline sodium salt (TOPS) coupled with 4-amino-antipyrine (4-AAP) by the action of hydrogen peroxide to give an obvious purple product. Platinum 0-8 albumin Homo sapiens 57-70 25051913-1 2014 Our aim was to evaluate the prognostic role of the pretreatment serum albumin level in patients with malignant pleural mesothelioma (MPM) receiving platinum-based systemic chemotherapy. Platinum 148-156 albumin Homo sapiens 70-77 25051913-11 2014 The pretreatment serum albumin level is a simple, inexpensive and easily measurable marker with prognostic significance in MPM patients treated with platinum-based systemic chemotherapy. Platinum 149-157 albumin Homo sapiens 23-30 22077361-0 2011 Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin. Platinum 61-69 albumin Homo sapiens 88-101 22077361-1 2011 Interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the metabolism, distribution, and efficacy of platinum-based anticancer drugs. Platinum 21-29 albumin Homo sapiens 50-63 22077361-1 2011 Interactions between platinum complexes and human serum albumin (HSA) play crucial roles in the metabolism, distribution, and efficacy of platinum-based anticancer drugs. Platinum 138-146 albumin Homo sapiens 50-63 19070448-2 2009 This study was designed to examine the interaction between the platinum-based anticancer drug, oxaliplatin, with human serum albumin (HSA) in aqueous solution at physiological pH with drug concentrations of 10 to 100 microM and a constant concentration of HSA (5.0 x 10(-5)M). Platinum 63-71 albumin Homo sapiens 125-132 18586468-0 2008 Bovine serum albumin adsorption on nano-rough platinum surfaces studied by QCM-D. Platinum 46-54 albumin Homo sapiens 7-20 29144983-0 2018 Albumin-coordinated assembly of clearable platinum nanodots for photo-induced cancer theranostics. Platinum 42-50 albumin Homo sapiens 0-7 29144983-3 2018 Here, we introduce albumin-coordinated assembly of clearable Pt nanodots (Pt-NDs) with monodisperse nanostructure as high-performance theranostic agents for imaging-guided photothermal tumor ablation. Platinum 61-63 albumin Homo sapiens 19-26 32264286-0 2017 Albumin-mediated platinum nanocrystals for in vivo enhanced computed tomography imaging. Platinum 17-25 albumin Homo sapiens 0-7 32264286-3 2017 Herein, a simple albumin-directed fabrication of platinum (Pt) nanocrystals was achieved for exploring the utilization in CT imaging. Platinum 49-57 albumin Homo sapiens 17-24 32264286-3 2017 Herein, a simple albumin-directed fabrication of platinum (Pt) nanocrystals was achieved for exploring the utilization in CT imaging. Platinum 59-61 albumin Homo sapiens 17-24 27484966-9 2016 The investigations on how picoplatin interacts with HSA are important for the understanding of the anticancer mechanism and toxicity of platinum-based anticancer drug. Platinum 136-144 albumin Homo sapiens 52-55 25375839-4 2015 Spectroscopic studies of both platinum derivatives reveal their ability to interact unequivocally with DNA from calf thymus and DNA of low molecular weight from salmon sperms, and also with the most abundant protein in human blood plasma, human serum albumin (HSA). Platinum 30-38 albumin Homo sapiens 245-258 25732554-0 2015 Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs. Platinum 35-43 albumin Homo sapiens 89-102 25732554-0 2015 Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs. Platinum 35-43 albumin Homo sapiens 119-122 25732554-4 2015 This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications. Platinum 159-167 albumin Homo sapiens 67-70 25732554-4 2015 This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications. Platinum 159-167 albumin Homo sapiens 205-208 25732554-4 2015 This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications. Platinum 159-167 albumin Homo sapiens 205-208 24902769-2 2014 We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery. Platinum 28-36 albumin Homo sapiens 106-119 23052861-1 2013 This study focuses on the identification of the products that are formed upon binding of therapeutically relevant platinum complexes to proteins like beta-lactoglobulin A (LGA), human serum albumin (HSA), or human hemoglobin (HB). Platinum 114-122 albumin Homo sapiens 184-197 17992278-2 2007 The interactions of polynuclear platinum complexes with human serum albumin were studied. Platinum 32-40 albumin Homo sapiens 62-75 11283915-5 2001 Avidin was also adsorbed onto bovine serum albumin (BSA)-coated surfaces of oxide and platinum. Platinum 86-94 albumin Homo sapiens 37-50 15237398-0 2004 Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin. Platinum 0-8 albumin Homo sapiens 188-201 15237398-1 2004 Characterizing how platinum metallocomplexes bind to human serum albumin (HSA) is essential in evaluating anticancer drug candidates. Platinum 19-27 albumin Homo sapiens 59-72 8681412-1 1996 The adsorption behavior of serum albumin onto the surface of platinum, gold, and glassy carbon electrodes was studied in relation to the electrode potential, by using cyclic voltammetry and a quartz-crystal microbalance. Platinum 61-69 albumin Homo sapiens 27-40 17014801-1 1992 The process of adsorption of bovine serum albumin onto a platinum electrode was monitored through the measurement of a nonlinear electrochemical property. Platinum 57-65 albumin Homo sapiens 36-49 8074278-0 1994 Application of polymer-protected ultrafine platinum particles to the immunological detection of human serum albumin. Platinum 43-51 albumin Homo sapiens 102-115 7859338-0 1994 Electrochemically accelerated adsorption of serum albumin on the surface of platinum and gold electrodes. Platinum 76-84 albumin Homo sapiens 44-57 7859338-1 1994 Adsorption of serum albumin on the surface of platinum and gold electrodes was highly accelerated by the application of a constant potential to the electrodes. Platinum 46-54 albumin Homo sapiens 14-27 34703544-0 2021 Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Platinum 46-54 albumin Homo sapiens 0-7 2323620-0 1990 Serum albumin: its relationship to marrow and renal toxicity from platinum-based combination chemotherapy. Platinum 66-74 albumin Homo sapiens 0-13 34703544-8 2021 KP2156 forms very stable albumin adducts in the bloodstream resulting in a superior pharmacological profile, such as distinctly prolonged terminal excretion half-life and enhanced effective platinum dose (measured by ICP-MS). Platinum 190-198 albumin Homo sapiens 25-32 34703544-11 2021 Summarizing, albumin-binding of platinum(iv) complexes potently enhances the efficacy of oxaliplatin therapy and should be further developed towards clinical phase I trials. Platinum 32-40 albumin Homo sapiens 13-20 3941800-3 1986 The decrease in serum albumin from the time of the first dose of cisplatin to death correlated with liver platinum levels at autopsy (r = 0.46, p less than 0.05). Platinum 106-114 albumin Homo sapiens 16-29 35286638-3 2022 The Pt(IV)-lonidamine complex interacts with albumin relatively slowly but possesses high stability and lipophilicity (log P 1.62), which makes it possible the cellular uptake in a free (of proteins) form. Platinum 4-6 albumin Homo sapiens 45-52 35062908-0 2022 Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma. Platinum 53-61 albumin Homo sapiens 11-18 35062908-1 2022 BACKGROUND: This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC). Platinum 101-109 albumin Homo sapiens 67-74 3941800-4 1986 The decrease in serum albumin concentration associated with liver platinum concentration of less than or equal to 1.5 micrograms/g was 0.16 +/- 0.23 g/dl (range 0-0.6). Platinum 66-74 albumin Homo sapiens 16-29 33616009-0 2021 Spectroscopic and docking molecular study of new anticancer Pt complex binding with human serum albumin. Platinum 60-62 albumin Homo sapiens 90-103 33951465-3 2021 Here, we report that KIM-1 mediates PT uptake of palmitic acid (PA)-bound albumin, leading to enhanced tubule injury with DNA damage, PT cell-cycle arrest, interstitial inflammation and fibrosis, and secondary glomerulosclerosis. Platinum 36-38 albumin Homo sapiens 74-81 7272330-3 1981 Serum albumin, which itself has a surface tension of congruent to 70.3 erg/cm2, when dissolved in water lowers the surface tension of water from 72.5 to congruent to 50 erg/cm2, as measured by a variety of means, including the pendant drop, the Wilhelmy plate and the platinum ring methods. Platinum 268-276 albumin Homo sapiens 0-13 33596034-0 2021 Spectroscopic characterization of the interactions of bovine serum albumin with medicinally important metal ions: platinum (IV), iridium (III) and iron (II). Platinum 114-122 albumin Homo sapiens 61-74 33616009-1 2021 After synthesizing and identifying the nature of the new complex based on platinum metal, [Pt(NH3)2(butylgly)]NO3, the interaction of this complex with human serum albumin (HSA) was performed by spectroscopy and molecular docking methods at two temperatures of 27 and 37 C and under physiological conditions of the body. Platinum 74-88 albumin Homo sapiens 158-171 32928400-3 2020 Based on this, the nanozyme of bovine serum albumin-Pt nanoparticles@mesoporous MnCo2O4 (BSA-PtNP@MnCo2O4) was successfully synthesized and used to construct enzyme cascade bio-platform. Platinum 52-54 albumin Homo sapiens 38-51 32771026-13 2020 Elevated D-dimer and reduced albumin might be potential biomarkers for worse response to first-line platinum-based chemotherapy and poor clinical outcomes. Platinum 100-108 albumin Homo sapiens 29-36